CVS Group stock rises after meeting profit expectations despite revenue miss

CVS Group shares gained 4% after the company reported fiscal year 2025 revenue of £673 million, 1% below consensus, yet met adjusted EBITDA expectations of £134 million. The revenue miss was attributed to softer UK market conditions, though the company noted Q4 improvement. Strategically, CVS Group has significantly expanded in Australia with 30 practice acquisitions, while UK acquisition activity is on hold pending a CMA investigation, though management remains confident in future opportunities. The company also improved its leverage to 1.2x and anticipates further inorganic growth, reaffirming its mid-term margin guidance.

Analysis

CVS Group presented a mixed but resilient fiscal year 2025 performance, leading to a 4% share price increase. While revenue of £673 million marked a 5.4% year-over-year growth, it fell 1% short of consensus estimates, a miss attributed to soft UK market conditions that resulted in minimal like-for-like growth of just 0.2%. Despite this top-line softness, the company demonstrated strong operational control by meeting analyst expectations for adjusted EBITDA at approximately £134 million, achieving a robust margin of around 20%. This signals effective cost management and profitability preservation. Strategically, the company is successfully executing an inorganic growth plan in Australia, completing 15 practice acquisitions during the year, while its UK M&A activity remains paused pending a Competition and Markets Authority (CMA) investigation. The balance sheet has been significantly strengthened, with leverage reduced to 1.2x from 1.7x, aided by £42 million in proceeds from a business disposal, positioning the company well within its sub-2x target. Although specific guidance for fiscal year 2026 was not provided, management reaffirmed its mid-term margin target of 19-23% and anticipates further inorganic growth, supported by signs of market improvement in the final quarter.

Key Decisions for Investors

• Investors should weigh the company's proven ability to maintain strong EBITDA margins and expand internationally against the continued weakness in UK like-for-like sales.
• The upcoming preliminary decision from the UK's Competition and Markets Authority in September is a critical catalyst; a favorable outcome could remove a major overhang and unlock pent-up UK acquisition activity.
• Consider the company's improved financial position, with leverage at a conservative 1.2x, which provides significant capacity to fund its inorganic growth strategy in Australia and potentially the UK.
• Pay close attention to the full fiscal year results on October 7 for any commentary on the recovery of UK consumer demand, as a rebound in organic growth would substantially strengthen the investment thesis.